08.11.2014 Views

Here - American Geriatrics Society

Here - American Geriatrics Society

Here - American Geriatrics Society

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

P OSTER<br />

A BSTRACTS<br />

D28<br />

Interactive video dance and cognition: baseline data.<br />

J. Jovancevic- Misic, S. A. Studenski, Y. Zheng, S. Perera. University<br />

of Pittsburgh, Pittsburgh, PA.<br />

Supported By: The research reported in this abstract was supported<br />

by NIH- Claude D Pepper Older <strong>American</strong>s Independence Center<br />

Grant, P30 AG024827, and by T32 grant (AG21885).<br />

Purpose: Though some evidence exists that physical exercise has<br />

the potential to affect cognitive function, the majority of evidence relates<br />

to the cognitive effects of fitness training. There is evidence that<br />

video games may induce cognitive improvement and generalize to<br />

daily function, but mostly do not involve physical exercise. Little is<br />

known of how combining these two types of training might impact<br />

cognition, or the role of participants’ cognitive status on their success.<br />

The purpose of this study is to examine the role of visual attention in<br />

learning to process visual info in interactive video dance. Relative<br />

value of participants’ previous experience with video games and<br />

some types of leisure activities in predicting their performance on the<br />

video dance was also investigated.<br />

Methods: This is a cross sectional analysis of the baseline data<br />

from a RCT Adherence and health effects of video dance exercise<br />

and brisk walking in postmenopausal women. We focus on the baseline<br />

data of the interactive video dance group. Participants were 46<br />

overweight, sedantary women aged 50-65. Repeatable Battery for the<br />

Assessment of Neuropsychological Status (RBANS) test, the Useful<br />

Field of View (UFOV) test and Leisure activity questionnaire were<br />

administered at baseline. Participants’ previous experience with<br />

video games, and ability to master the basics of interactive video<br />

based dance on the first day was noted.<br />

Results: We analyzed the association between two cognitive domains<br />

(attention and visuo-spatial) as measured by RBANS and attention<br />

deployment and visuo-spatial skills (UFOV). All domains<br />

were correlated (Table 1).<br />

Performance on cognitive tests as predictors of success in finishing<br />

video dance lessons the first day was analyzed. The test of divided<br />

attention (UFOV) and RBANS (attention) score tended to have an<br />

impact, though only RBANS effect was significant (p=0.03). Previous<br />

experience with dance and video games was found to have no effect<br />

on the success of video dance performance.<br />

Conclusions: Baseline data indicates that UFOV reflects some<br />

RBANS factors and as such may be related to early success with<br />

learning video dance. Further it would appear that no prior experience<br />

playing video games or dancing is necessary for mastering this<br />

new skill.<br />

D30 Encore Presentation<br />

Skeletal muscle sampling in elderly research participants with<br />

chronic disease.<br />

M. F. Lyles, J. L. Demons, K. M. Murphy, B. J. Nicklas. Internal<br />

Medicine, Wake Forest School of Medicine, Winston Salem, NC.<br />

Supported By: Claude Pepper Older <strong>American</strong>s Independence<br />

Center (1P30 AG21332, WFU General Clinical Research Center<br />

(M01-RR07122), National Institute on Aging (R37 AG018915)<br />

Deficits in skeletal muscle metabolism and function are major<br />

contributors to development of disability in older adults. The conduct<br />

of in vitro experiments of muscle metabolism and function is important<br />

for advancing understanding of aging-related disability progression.<br />

Percutaneous muscle biopsy techniques are widely utilized in<br />

studies of young and/or healthy persons, but are underutilized in the<br />

elderly, especially those with chronic illness, who are at the highest<br />

risk of becoming disabled. The goal of this project was to determine<br />

the feasibility, safety and tissue yield of muscle biopsies performed in<br />

older adults with common chronic diseases enrolled in several clinical<br />

trials. A total of 324 biopsies were performed in research participants<br />

with COPD, CHF, osteoarthritis or obesity, who were enrolled in clinical<br />

trials of weight loss and/or exercise training. Only minor modifications<br />

in safety procedures, such as adjustment of table position,<br />

were needed for biopsy performance in these patients. The average<br />

tissue yield of for all biopsies was 157±90 mg. Participants in which<br />

muscle was obtained (81%) were compared to those in which only<br />

adipose tissue was obtained (19%; Table 1). Successful acquisition of<br />

skeletal muscle was more challenging in women and in more obese<br />

participants. The return rate for post-intervention biopsy was >90%.<br />

Percutaneous muscle biopsy is a feasible, safe and acceptable procedure<br />

in older adults with chronic diseases and provides a tool to understanding<br />

the development of disability in this group.<br />

Characteristics of participants with and without muscle tissue yield<br />

*Average yield = 157±90 mg<br />

D31 Encore Presentation<br />

Extended-release memantine (28 mg, once daily) and sustained<br />

cognitive improvement: Post hoc responder analysis from a<br />

randomized trial in patients with moderate to severe Alzheimer’s<br />

disease.<br />

M. Tocco, 1 S. Hendrix, 2 M. L. Miller, 3 V. Pejovic, 3 S. M. Graham. 1 1.<br />

Forest Research Institute, Jersey City, NJ; 2. Pentara Corporation,<br />

Salt Lake City, UT; 3. Prescott Medical Communications Group,<br />

Chicago, IL.<br />

Supported By: Supported by Forest Laboratories, Inc.<br />

Background: Alzheimer’s disease (AD) trials routinely report<br />

mean score differences between treatment groups; however, it is also<br />

important to compare percentages of patients who respond to treatment.<br />

An extended-release (ER) formulation of memantine (28 mg,<br />

once daily) was recently approved in the US based on a 24-week, randomized,<br />

placebo-controlled trial (NCT00322153) in patients with<br />

moderate to severe AD concurrently taking a cholinesterase inhibitor.<br />

Memantine ER-treated patients significantly outperformed<br />

placebo-treated patients on several outcome measures, including the<br />

Severe Impairment Battery (SIB), an instrument for assessing cognition<br />

in severely demented patients. In this post hoc analysis, we determined<br />

the percentages of patients who achieved a positive response<br />

on the SIB and maintained it throughout the trial.<br />

Methods: Five SIB response levels to double-blind treatment<br />

were selected (improvements of ≥0, ≥5, ≥10, ≥15, and ≥20 points), corresponding<br />

to 0, 0.5, 1.0, 1.5, and 2.0 standard deviations of the observed<br />

baseline-to-endpoint score change. Numbers of patients (observed<br />

cases) in each group who attained such responses at Weeks 4,<br />

8, 12, or 18 and maintained them through Week 24 (Endpoint) were<br />

compared using Fisher’s exact test, without correcting for multiple<br />

comparisons.<br />

Results: The mean (± SD) Baseline SIB score for the intent-totreat<br />

population (N=661) was 76.1 ± 18.4. A total of 523 patients (memantine<br />

ER, 261; placebo, 262) had available SIB data at all visits.<br />

Significantly more patients in the memantine ER group than the<br />

placebo group maintained Week 8 SIB responses of ≥5 points (26.1%<br />

vs 17.0%; P=0.014) and ≥10 points (14.6% vs 7.6%; P=0.012) through<br />

Endpoint. Similar differences in response maintenance were observed<br />

for responses attained at Week 12 (≥5 points: 28.5% vs 19.9%,<br />

P=0.025; ≥10 points: 16.3% vs 8.2%, P=0.005; ≥15 points: 9.5% vs<br />

4.1%, P=0.015) and Week 18 (≥10 points: 18.8% vs 10.0%, P=0.004;<br />

≥15 points: 10.9% vs 4.5%, P=0.006). No other significant betweengroup<br />

differences were observed.<br />

Conclusions: In this post hoc analysis, memantine ER was associated<br />

with cognitive improvement attained after 8-18 weeks and sustained<br />

through study endpoint.<br />

AGS 2012 ANNUAL MEETING<br />

S197

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!